HFA Icon
About Us My Account
Account Icon
Search
Subscribe

Kyle Bass Lives Up To Big Pharma Patent Challange

HFA Padded
Mark Melin
Published on
Updated on
Sign up for our E-mail List and Get FREE Access to Exclusive Investment E-books and More!

Legal papers from Kyle Bass-backed group challenge biotech company on their patents

Kyle Bass, founder of Dallas-based hedge fund Hayman Capital Management, appears to be making good on his announced plans to play Robin Hood with the top pharmaceutical companies.

Bass has now filed his first Inter Partes Review, a legal move challenging big pharma and their control over drug distribution and prices. His first target: Acorda Therapeutics, a biotechnology company based in Ardsley, New York. Their drugs primarily target neurological functions in people with multiple sclerosis.

Kyle Bass Lives Up To Big Pharma Patent Challange
Image: Logo

 

Kyle Bass-backed legal challenge...

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article
Already a member? Log in here

HFA Padded
Mark Melin

Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.

More articles of the author

Get Your Business News

Get articles and insights from our weekly newsletter.

By entering your email, you agree to our Terms of Service and Privacy Policy.

295 Madison Avenue 12th floor
New York, NY 10017 Phone: 973-685-6523
Email: [email protected]

© Copyright 2025 Hedge Fund Alpha. All Rights Reserved.